Dual incretin receptor agonist
Tirzepatide
LY3298176 — dual GIP / GLP-1 receptor agonist
Overview
Tirzepatide is a single, once-weekly injectable medicine that activates two gut-hormone receptors at the same time: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is the first approved dual incretin agonist and the first weight-management medicine to show mean body-weight reductions in the low-to-mid twenties percentage range across large phase-3 trials.
It is marketed as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Both are the same molecule at the same dose range — only the label and the studied population differ.
Mechanistically, tirzepatide acts on pancreatic beta cells (glucose-dependent insulin release, glucagon suppression), on the gut (slowed gastric emptying, prolonged satiety), and in appetite-regulating regions of the brain (reduced hunger and food reward). Preclinical work characterises it as a biased and imbalanced agonist that engages GIPR more strongly than GLP-1R at the cellular level.
Quick Facts & Evidence
- Category
- Dual incretin receptor agonist
- Research area
- GLP-1 / GIP incretin agonist
- Most studied for
- Type 2 diabetes
- Chronic weight management (obesity)
- Cardiovascular outcomes (ongoing)
- Metabolic-associated steatotic liver disease (MASLD)
- Clinical status
- Established clinical use
- Human evidence
- Strong Human Evidence
- Regulatory status
- Approved in FDA, EMA, MHRA, PMDA
Strong Human Evidence
Backed by multiple large randomised controlled trials in humans and, where applicable, approval by major regulatory agencies.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format
This page covers the RUO lyophilized tirzepatide vial reconstituted with bacteriostatic water for subcutaneous research use, following the standard Healthy Mango preparation convention. The FDA-approved Mounjaro (T2D) and Zepbound (chronic weight management) pre-filled pens are separate commercial products cited only as scientific evidence (pharmacology, published trials, safety) — they are not the presentation described here.
Tirzepatide research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 60 mg |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 2.0 mL |
| Final concentration | 30 mg/mL |
| How it's given | Subcutaneous injection |
| Research dose | 1.25 mg starting; titrated toward a maintenance range up to ~15 mg once weekly (as studied in trials) |
| Frequency | Once weekly |
| After mixing | Refrigerate; use within 7–10 days |
Reported Dosing
Published tirzepatide trials start at 2.5 mg once weekly and titrate upward every 4 weeks toward a maintenance range up to ~15 mg. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg | Once weekly, subcutaneous | Continuous; titration typically 4 weeks per step | Weight-management titration studied in the SURMOUNT program |
| 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg | Once weekly, subcutaneous | Continuous; titration typically 4 weeks per step | T2D titration studied in the SURPASS program |
Why protocols vary
The 2.5 mg starting dose is a titration step to build GI tolerability; the 5 mg step is the first therapeutic dose in the trial ladder. Continued titration to 15 mg is optional depending on trial protocol and tolerability.
The compounded RUO lyophilized presentation is a research-supply format only; it is not equivalent to the FDA-approved Mounjaro/Zepbound pens and does not carry their post-marketing surveillance framework. This Snapshot describes the RUO form only.
Preparing the Solution
Turning the freeze-dried powder into a measurable liquid.
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 60 mg vial
Diluent: 2.0 mL bacteriostatic water
Final concentration: 30 mg/mL
Vial and volume from the practitioner reference; concentration calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
2mL
Resulting concentration
30 mg/mL
Equivalent volume
The reported research amount of 1.25–15 mg is contained within
0.0417–0.5000mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 60 mg ÷ 2 mL = 30 mg/mL
- Bacteriostatic water to match the documented concentration
- 60 mg ÷ 30 mg/mL = 2 mL
- Equivalent volume at this concentration
- 1.25–15 mg ÷ 30 mg/mL ≈ 0.0417–0.5 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner reference; dose range from SURPASS/SURMOUNT trial programsResearch-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO preparation. It is not a preparation guide, and it does not describe any FDA-approved product.
How It's Given
Method used for this format
Subcutaneous injection, once weekly
Published tirzepatide pharmacology (SURPASS, SURMOUNT programs) · Peer-reviewed study
Why this method
Tirzepatide is a modified 39-amino-acid dual GIP/GLP-1 agonist with a fatty-acid modification that binds serum albumin, giving an ~5-day half-life.
The once-weekly cadence matches the half-life, giving a steady dual-incretin signal without daily dosing.
Injection sites reported
- Abdomen (rotate sites)
- Thigh
- Upper arm
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light
- Do not freeze
General RUO practice · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within 7–10 days (compounded RUO)
- Do not freeze
- Discard if cloudy or discoloured
General RUO practice · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises standard RUO peptide handling for the compounded lyophilized presentation. FDA-approved Mounjaro and Zepbound pre-filled pens have their own labelled storage windows that apply to those separate products, not to this RUO vial.
Common Cycle
Published tirzepatide trials use continuous chronic dosing, not cycled therapy. Discontinuation trials (SURMOUNT-4) show meaningful weight regain within 6 months of stopping.
- Cycle Length
- Continuous chronic dosing
- Break Before the Next Cycle
- Not applicable
- What the Research Shows
- SURPASS (T2D) and SURMOUNT (obesity) programs followed participants for 40–88 weeks with maintained effect
SURPASS-1 through SURPASS-5; SURMOUNT-1 through SURMOUNT-4 · Peer-reviewed study
Continuous-use evidence is drawn from published trials of the approved product; extrapolation to compounded RUO material rests on the shared molecular identity, not on shared regulatory oversight.
Compound Overview
Current areas of research
The following are indications and effects for which tirzepatide has been studied. Regulatory approval is limited to the first two.
- Glycaemic control in adults with type 2 diabetes (FDA/EMA approved)
- Chronic weight management in adults with obesity or overweight with weight-related comorbidities (FDA/EMA approved)
- Reduction in visceral adipose tissue (secondary endpoints across SURMOUNT)
- Improvement in liver-associated markers in participants with MASLD — investigational
- Reduction in cardiovascular risk markers (blood pressure, triglycerides, LDL); dedicated CV outcomes trial (SURPASS-CVOT) is ongoing
Mechanism of action
Tirzepatide is a single, once-weekly injectable medicine that activates two gut-hormone receptors at the same time: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is the first approved dual incretin agonist and the first weight-management medicine to show mean body-weight reductions in the low-to-mid twenties percentage range across large phase-3 trials.
It is marketed as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Both are the same molecule at the same dose range — only the label and the studied population differ.
Mechanistically, tirzepatide acts on pancreatic beta cells (glucose-dependent insulin release, glucagon suppression), on the gut (slowed gastric emptying, prolonged satiety), and in appetite-regulating regions of the brain (reduced hunger and food reward). Preclinical work characterises it as a biased and imbalanced agonist that engages GIPR more strongly than GLP-1R at the cellular level.
- Consistent superiority to semaglutide in glycaemic and weight endpoints in head-to-head trials
- Effect sizes for weight reduction that approach post-bariatric-surgery outcomes in some subgroups
- A relatively clean pharmacological profile centred on gut hormones rather than centrally acting appetite suppressants
Human research
Tirzepatide has been evaluated across two large clinical programs: SURPASS (type 2 diabetes) and SURMOUNT (obesity). Both are multi-trial programs with tens of thousands of participants combined and long-term follow-up ongoing.
Evidence level for its approved indications is Level A — established clinical use, backed by multiple large randomised controlled trials and regulatory approvals in the US, EU, UK, and Japan.
SURPASS-1
Tirzepatide monotherapy in drug-naive adults with type 2 diabetes. Reduced HbA1c by ~2 percentage points at the highest dose over 40 weeks.
SURPASS-2
Head-to-head against once-weekly semaglutide 1 mg in T2D. Tirzepatide superior on HbA1c and body-weight endpoints across all three tested doses.
SURMOUNT-1
Adults with obesity, without diabetes. Mean body-weight reduction of ~20.9% at 72 weeks at the highest dose vs. ~3.1% with placebo.
SURMOUNT-2
Adults with obesity and type 2 diabetes. Mean weight loss ~15% at the highest dose, notably preserved despite co-existing T2D.
SURMOUNT-4
Weight-maintenance trial: participants who lost weight over an initial phase were randomised to continue tirzepatide or switch to placebo. Placebo group regained a substantial fraction of lost weight.
Tirzepatide is fully approved for clinical use. The FDA authorised Mounjaro (type 2 diabetes) in May 2022 and Zepbound (chronic weight management in adults with obesity or overweight with weight-related comorbidities) in November 2023. The EMA authorised Mounjaro for type 2 diabetes in September 2022 and extended the authorisation to include weight management in 2023. Approvals in the United Kingdom (MHRA), Japan (PMDA), and other jurisdictions have followed.
Beyond its approved indications, tirzepatide is being evaluated in ongoing phase-3 trials for cardiovascular outcomes (SURPASS-CVOT), heart failure with preserved ejection fraction (SUMMIT), obstructive sleep apnoea, and metabolic-associated steatotic liver disease (MASLD, formerly NAFLD). None of these secondary indications are currently approved.
Safety considerations
The following have been reported in the pooled SURPASS and SURMOUNT data and in prescribing information. Frequencies vary by dose; higher doses show higher incidence.
- Nausea — Most common; usually transient; peak during titration
- Vomiting
- Diarrhoea
- Constipation
- Reduced appetite and early satiety
- Injection-site reactions — Mild, localised
- Hypoglycaemia — Primarily when combined with insulin or sulphonylureas
- Cholelithiasis (gallstones) — Reported at higher incidence than placebo
- Acute pancreatitis — Rare; monitor for symptoms
- Diabetic retinopathy complications — Reported in some GLP-1-based trials in participants with pre-existing severe retinopathy
The contraindications below are drawn directly from the FDA and EMA labelling. Any decision about suitability should involve a qualified clinician with access to the individual's medical history. The dominant safety signal in trials is dose-dependent gastrointestinal effects during titration; rare but serious events include acute pancreatitis, gallbladder disease, acute kidney injury (secondary to dehydration from persistent vomiting or diarrhoea), and severe hypersensitivity. A boxed-style warning appears in the labelling regarding thyroid C-cell tumours based on rodent studies.
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to tirzepatide or any excipient in the product
- Pregnancy (per label; effective contraception recommended in individuals of reproductive potential)
- Breastfeeding — data are limited
Monitoring
- HbA1c and fasting glucose (diabetes)
- Weight and body composition
- Renal function during illness or dehydration
- Signs and symptoms of pancreatitis (severe abdominal pain radiating to the back)
- Vitamin and micronutrient status where intake is markedly reduced by appetite suppression
Frequently asked questions
How does tirzepatide compare to semaglutide?
SURPASS-2 was a head-to-head trial in type 2 diabetes: at every tested dose, tirzepatide produced a greater HbA1c reduction and greater weight loss than semaglutide 1 mg. In obesity populations, no adequately-powered head-to-head trial vs. semaglutide 2.4 mg has been published, but indirect comparisons and cross-trial analyses have consistently shown larger weight reductions with tirzepatide.
Is the weight loss maintained long-term?
SURMOUNT-4 randomised participants who had lost weight on tirzepatide to either continue or switch to placebo. The continuing group maintained or extended their loss; the placebo group regained a substantial fraction. Weight loss appears to be contingent on continued treatment.
What is the difference between Mounjaro and Zepbound?
They contain the same molecule, tirzepatide, at the same dose range. The two brand names correspond to different regulatory indications: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Pens and packaging differ; the active drug is identical.
Why does the label emphasise titration so heavily?
Gastrointestinal side effects (nausea, vomiting, diarrhoea) are dose-dependent and are the leading reason for discontinuation. The four-week titration schedule allows the body to adapt at each step, dramatically reducing the intensity of GI effects compared with starting at a therapeutic dose.
Can tirzepatide be combined with other diabetes medications?
The label discusses combination with metformin, SGLT2 inhibitors, sulphonylureas, and insulin. Combinations with insulin or sulphonylureas increase hypoglycaemia risk and typically require dose adjustment of those medications. All decisions in this space belong with a clinician.
References
- [1]
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1) — Rosenstock J, Wysham C, Frías JP, et al., The Lancet (2021)
- [2]
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) — Frías JP, Davies MJ, Rosenstock J, et al., New England Journal of Medicine (2021)
- [3]
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — Jastreboff AM, Aronne LJ, Ahmad NN, et al., New England Journal of Medicine (2022)
- [4]
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — Garvey WT, Frías JP, Jastreboff AM, et al., The Lancet (2023)
- [5]
Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4) — Aronne LJ, Sattar N, Horn DB, et al., JAMA (2024)
- [6]
FDA Prescribing Information — MOUNJARO (tirzepatide) injection — U.S. Food and Drug Administration (2022)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
- [7]
FDA Prescribing Information — ZEPBOUND (tirzepatide) injection — U.S. Food and Drug Administration (2023)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
- [8]
Mounjaro (tirzepatide) — European Public Assessment Report (EPAR) — European Medicines Agency (2022)
- [9]
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist — Willard FS, Douros JD, Gabe MBN, et al., JCI Insight (2020)
- [10]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.
Related
Related topics
Related on Healthy Mango
Guides
Categories